 GlycoMimetics may have discovered a successful treatment for AML leukemia, currently with a 5-year survival rate of around 30. Small research trial sizes have delivered exceptional results, with the U.S. FDA engaging in an Interim Utility Analysis of the companys uproleselan Phase 3 study. 